Athira Pharma reports Q3 2025 net loss of $6.6M, cash at $25.2M; exploring strategic alternatives

LeonaBio, Inc.

2025-Q3 EPS reported -$5.80

Net loss of $6.6M ($1.68 per share) vs $28.7M ($7.46 split-adjusted) in Q3 2024.
Cash and investments $25.2M as of Sept 30, 2025, down from $51.3M at Dec 31, 2024.
R&D expenses fell to $2.8M from $17.9M; G&A expenses $4.1M vs $7.6M year-over-year.
Company continues to explore strategic alternatives to maximize stockholder value; engaged Cantor Fitzgerald.
Phase 1 data for ALS candidate ATH-1105 showed favorable safety, dose-proportional PK, and CNS penetration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.